OTC : GIKLY

Grifols, S.A.

$5.1 USD

$0 (0.0%)

Volume
1
Average Volume
285
Market Capitalization
$13.4B
P/E Ratio
14.88
Dividend Yield
0.74%
Price Target
Year High
$7.49
Year Low
$5.06
Day High
—
Day Low
—
Payout Ratio
$0.31
Current Ratio
$2.47
Company Overview

OTC

Jose Ignacio Abia Buenache

Drug Manufacturers - General

Healthcare

GIKLY

25258

ES

USD

https://www.grifols.com

34 93 571 02 21

398438200

0001438569

Liquidity Metrics

1.77

2.47

0.85

0.33

0.31

Sales & Valuation

$7.52B

0.83

1.13

8.20

0.55

Profitability

$0.28

$386.03M

5.58%

8.23%

7.88%

2.07%

P/E Metrics

14.88

0.13

0.13

Analyst Price Target & Rating

Neutral

3/5

7 Analysts

%

Poll Results

About Grifols, S.A. (OTC:GIKLY) Stock

Grifols, S.A. is a company dedicated to the acquisition, production, processing, and distribution of therapeutic goods, with a primary focus on plasma-derived medicines. Its operations are structured across several key divisions: Bioscience, Hospital, Diagnostic, Bio Supplies, and other segments. The Bioscience unit is responsible for researching, developing, manufacturing, and marketing plasma-based medications and other cutting-edge treatments. These solutions address chronic, rare, widespread, and life-threatening conditions. Its extensive product line includes immunoglobulins, alpha-1 antitrypsin, albumin, various clotting factors, and hyperimmune globulins. Through its Hospital division, Grifols provides non-biological pharmaceuticals and a range of medical supplies, such as items for ... clinical nutrition, intravenous treatment, and diverse medical devices. The Diagnostic division concentrates on the research, development, production, and commercialization of diagnostic tools for healthcare professionals. These products encompass the entire patient care journey, from initial prevention and screening to diagnosis, prognosis, and the ongoing monitoring of diseases and treatments. Furthermore, the Bio Supplies division furnishes biological components essential for life-science research, clinical investigations, and the manufacturing of both pharmaceutical and diagnostic products. Healthcare providers globally rely on Grifols' offerings to diagnose and manage a variety of conditions, including hemophilia, immune system disorders, infectious diseases, and numerous other health issues. Its broad client base spans both public and private entities, encompassing wholesalers, distributors, collective purchasing groups, blood banks, hospitals, various care facilities, and national healthcare systems. Grifols, S.A. also maintains a technological partnership with Mondragon. Established in 1940, the company's corporate headquarters are situated in Barcelona, Spain.

Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)

2026-07-03 10:49:07

First-quarter results were broadly in line with expectations, supported by strong growth in the Biopharma division, particularly immunoglobulins, where products such as Gamunex and Yimmugo continue to outperform. Grifols successfully refinanced all 2027 debt maturities ahead of schedule, extending maturities, lowering funding costs, and reducing refinancing risk. Lower plasma collection costs (with the Egyptian plasma platform), optimization of the U.S. collection network, and continued Biotest integration are expected to support sustainable margin expansion.

Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.

2026-06-15 08:00:00

BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency (CFD), including hypo- or afibrinogenemia, FESILTY™ (fibrinogen, human-chmt) is now available in the U.S. FESILTY is not indicated for dysfibrinogenemia.

Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript

2026-05-09 15:31:13

Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript

Frequently Asked Questions

What is the current Grifols, S.A. (GIKLY) stock price?

Grifols, S.A.(OTC:GIKLY) stock price is $5.1 in the last trading session. During the trading session, GIKLY stock reached the peak price of $7.49 while $5.06 was the lowest point it dropped to. The percentage change in GIKLY stock occurred in the recent session was 0.0% while the dollar amount for the price change in GIKLY stock was $0.

GIKLY's industry and sector of operation?

The OTC listed GIKLY is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.

Who are the executives of GIKLY?

Lluis Pons Gomez | Senior Vice President of Strategy & Chief Operating Officer Office
Montse Ribas | Chief Communications and Reputation Officer
Rahul Srinivasan | Chief Financial Officer
Ignacio Ramal Subira | Chief Internal Audit & Enterprise Risk Manager
Camille Alpi | Chief Human Resources & Talent Officer

How many employees does GIKLY have?

Number of GIKLY employees currently stands at 25258. GIKLY operates from Avinguda de la Generalitat, 152, Barcelona, CT 08174, ES.

Link for GIKLY official website?

Official Website of GIKLY is: https://www.grifols.com

How do I contact GIKLY?

GIKLY could be contacted at phone #34 93 571 02 21 and can also be accessed through its website. GIKLY operates from Avinguda de la Generalitat, 152, Barcelona, CT 08174, ES.

How many shares of GIKLY are traded daily?

The average number of GIKLY shares traded daily for last 3 months was 285.

What is the market cap of GIKLY currently?

The market value of GIKLY currently stands at $13.4B with its latest stock price at $5.1